Hillary Clinton Is Targeting Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has a number of targets on its back.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares plunged once again on Thursday after Hillary Clinton called out the company at a campaign appearance. Here is what she had to say:

This is a letter from someone who’s here. And she gave me this letter. She has to take a brand name drug. She’s been taking it since the early 1980s. At that time, back in the 1980s, for the same drug, it cost approximately $180 for 10 shots. The latest refill she received from her pharmacy was $14,729.99 for the same 10 vials. And the company is one of these companies that is absolutely gouging American consumers and patients. It’s called Valeant Pharmaceuticals. I’m going after them. We are going to stop this. This is predatory pricing. It is unjustified. It is wrong. And we’re going to make sure it is stopped.

At the end of these remarks, the Iowan crowd gave her a standing ovation, which is a fair reflection of how Americans feel about the issue.

So what exactly does this mean for Valeant?

The stars are aligned

Normally, it is very difficult to get legislation passed in Washington. But this issue has strong bipartisan support. To illustrate, in a recent survey by the Kaiser Family Foundation, 83% of Americans favour the idea of letting Medicare negotiate for lower drug prices, including 74% of Republicans.

With that kind of bipartisan support, there’s a chance of legislation even if a Republican gets elected. For what it’s worth, Donald Trump has said that Medicare should negotiate for discounted prices.

Alarmingly for Valeant, the company can’t even get any support from PhRMA, the pharmaceutical industry’s main lobby group. Back in October PhRMA posted an article on its website entitled “What makes Valeant different than innovative biopharmaceutical companies?” PhRMA noted in the article how Valeant spent only 3% of revenue on research and development in 2014 and compared the company to the much-maligned Turing Pharmaceuticals.

Is the stock still cheap enough?

There are a lot of people who still think Valeant is worth owning. To illustrate, 13 analysts rate the stock “Strong Buy” or “Buy” while only one rates the stock “Underperform,” according to Yahoo Finance. And it’s easy to see why–the company trades at a massive discount to its peers.

But let’s not forget that Valeant is the subject of a number of investigations, and we still haven’t gotten to the bottom of its relationship with Philidor. Making matters worse, the company has US$30 billion in debt, so there isn’t much room for error. In my opinion, the stock is simply too risky and there are better options for your portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

up arrow on wooden blocks
Dividend Stocks

2 High-Yield Dividend Stocks You Can Buy and Hold for a Decade

Restaurant Brands International (TSX:QSR) and another high-yield dividend payer are worth banking on for the long haul.

Read more »

hand stacks coins
Investing

Where Will Brookfield Corporation Stock Be in 10 Years?

Brookfield (TSX:BN) did well last decade. Will it thrive in the next one?

Read more »

think thought consider
Dividend Stocks

Restaurant Brands International: Buy, Sell, or Hold in 2025?

Investors should look more closely at QSR stock and potentially buy on the recent weakness.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

Maximizing Returns with Your 2025 TFSA Contribution Room

The TFSA is a top tool for maximizing investment returns. Here are two stocks that could be a great buy…

Read more »

woman retiree on computer
Dividend Stocks

Should You Buy Telus Stock at $20?

Down 40% from all-time highs, Telus is a beaten-down TSX dividend stock that trades at a discount to consensus price…

Read more »

top TSX stocks to buy
Dividend Stocks

Here’s Exactly How $15,000 in a TFSA Could Grow Into $200,000

Canadians with sizeable TFSA balances today have utilized the full potential of the investment vehicle.

Read more »

clock time
Investing

Building Generational Wealth: Why Now Is Still the Time to Invest in Canadian Stocks

Here's why Canadian stocks should still be the core of your investment portfolio.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

The 1 Canadian Stock I’d Buy and Hold Forever in a TFSA

Don't get complicated. Consider this Canadian stock as a long-time buy.

Read more »